Expert Interviews

Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.

Following the 2022 ASH Annual Meeting and Exposition, Peter Voorhees, MD; Amrita Krishnan, MD; and Josh Richter, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in blood cancer, as well as what research needs more follow-up.

The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.

Centering discussion on a recent study, experts Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on long-term data with tagraxofusp in BPDCN.

Expert hematologist-oncologists share their perspective on the broad diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.

Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.

John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.

A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.

Experts offer insights on the appropriate treatment for patients with HER2-positive metastatic colorectal cancer.

Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.

A video preview for an upcoming program reviewing clinical trial data and updates in the multiple myeloma treatment landscape over the last year.

A video preview for an upcoming expert panelist discussion of recent updates in the multiple myeloma treatment landscape.

Following the 2022 ASH Annual Meeting and Exposition, Nakhle Saba, MD; Lindsey Roeker, MD; Javier Pinilla, MD, PhD; and Catherine C. Coombs, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in chronic lymphocytic leukemia and lymphoma, as well as what research needs more follow-up.

Ravi Vij, MD, MBA, suggested that 4-drug regimens may be a new standard for frontline therapy in newly diagnosed multiple myeloma, as oncologists await trial readouts from ongoing clinical trials.

Ravi Vij, MD, MBA, offered additional information about the use of various regimens aimed to treat patients with high-risk, newly diagnosed multiple myeloma, that were read out at the 2022 ASH Annual Meeting.

Ravi Vij, MD, MBA, discussed updated analyses of the phase 3 SWOG S0777 trial, supporting the use of bortezomib, lenalidomide, and dexamethasone in untreated patients with multiple myeloma who do not plan on receiving immediate autologous stem cell transplant.

Susan O’Brien, MD, provides a brief overview of chronic lymphocytic leukemia (CLL), and Seema Ali Bhat, MD, explains the mechanism of BTK inhibitors.

“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.

Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.